Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › osteogenesis imperfecta

Osteogenesis imperfecta

Part of Osteochondrodysplasias

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for osteogenesis imperfecta

10 trials tracked for osteogenesis imperfecta: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 215 citations.

10Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 3 Phase 1 2 Other / NA 3
  1. Phase 4 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta Completed · 215 cited
  2. Phase 4 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed
  3. Phase 3 Growth Hormone Therapy in Osteogenesis Imperfecta Completed
  4. Phase 3 Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children Completed
  5. Phase 3 Pamidronate to Treat Osteogenesis Imperfecta in Children Completed
  6. Phase 1 Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta Completed
Show 4 more trials
  1. Phase 1 Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta Completed
  2. N/A Ready to Sail: Evaluating Sailing's Feasibility as Ergotherapy Completed
  3. N/A Post-market Observational Study on JTIN Telescopic Nail in Osteogenesis Imperfecta Pediatric Patients Completed
  4. N/A Prevention of Post Operative Bone Loss in Children Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Osteogenesis imperfecta: what the trials found

Pharmacological management of osteogenesis imperfecta includes several established agents. Teriparatide (FORTEO) 2, Alendronate 3, Humatrope 4, and Pamidronate (Aredia) 5 have been evaluated in clinical trials for this condition.

Risedronate sodium (Actonel) demonstrated a significant increase in lumbar spine bone mineral density (BMD) at 12 months (7.592% to 16.159%; p<0.0001) 6. However, the significance of BMD increases for risedronate at 24 months (p=0.0625) and 36 months (p=0.6103) was not established 6.

Recent results — preliminary, needs further review

  • JTIN implantation surgery showed a 100% implant survival rate and a 100% bone union achievement rate, with 4.0% of procedures involving at least one serious or non-serious adverse event potentially related to the device 1.

For the clinician treating this condition

  • Risedronate sodium shows statistically significant improvements in lumbar spine BMD at 12 months, though long-term significance (24-36 months) is not established.
  • Multiple pharmacological agents including Teriparatide, Alendronate, Humatrope, and Pamidronate are utilized in the management of osteogenesis imperfecta.
  • JTIN implantation surgery demonstrates high rates of bone union and implant survival.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ALFN fixation combined with zoledronic acid may stabilize fractures in adolescent patients with Osteogenesis Imperfecta
Orthopedics & Sports Medicine Sys. Review
ALFN fixation combined with zoledronic acid may stabilize fractures in adolescent patients with Osteogenesis Imperfecta New surgical method helps stabilize fractures in children with brittle bones
This case report and literature review describes a 13-year-old male with Sillence type III OI treated with ALFN fixation and intravenous zol…
A new surgical technique combined with medication may help stabilize and heal broken bones in children with a condition that makes bones fra…
Frontiers Jul 25, 2026
Whole exome sequencing identifies pathogenic variants and genotype-phenotype correlations in osteogenesis imperfecta
Genetics & Precision Medicine Cohort
Whole exome sequencing identifies pathogenic variants and genotype-phenotype correlations in osteogenesis imperfecta New Genetic Clues Explain Why Some Bone Cases Are More Severe
This cohort study evaluated 77 Chinese families with clinically suspected osteogenesis imperfecta using whole exome sequencing and clinical …
A new study of 77 Chinese families found 21 new genetic causes of brittle bone disease and showed that where the error sits in a key protein…
Frontiers Apr 29, 2026